randomized 2
study 2
melphalan 1
mgm 2
vs 1
preparative 1
regimen 1
patients 2
multiple 1
myeloma 1
undergoing 1
autosct 1
phase 2
ii 1
trial 2
comparing 1
obinutuzumab 1
ga 1
rituximab 1
relapsed 1
cd 1
indolent 1
bcell 4
nonhodgkin 1
lymphoma 7
final 1
analysis 2
gauss 1
gray 1
zone 1
features 1
intermediate 1
between 1
classical 1
hodgkin 1
diffuse 2
large 3
characteristics 1
outcomes 1
prognostication 1
among 1
multicenter 1
cohort 1
ibritumomab 1
consolidation 2
cycles 1
chop 2
plus 1
radiotherapy 1
highrisk 1
limitedstage 1
aggressive 1
swog 2
s 2
rchop 1
iodine 1
tositumomab 1
advanced 1
stage 1
dlbcl 1
comparative 1
prognostic 1
factor 1
models 1
follicular 1
based 1
iii 1
choprituximab 1
versus 1
iodinetositumomab 1
